Payment overview · 2025
General Payments
$312.11
27 reported records · 8 companies
Healthcare provider profile · identity verified
Darryl B Best, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREENWOOD, SC · NPI 1215973219
Verified facts
What the public records show
CMS Open Payments records show Darryl B Best, M.D. received $312.11 in general payments during 2025 across 27 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 53.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $165.55 | 53.0% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.18 | 10.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.89 | 8.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.51 | 7.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.60 | 6.3% | 1 | 2025 |
| Atland Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.78 | 5.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.88 | 4.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.72 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $312.11 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $165.55 | 18 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.89 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.89 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.51 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE Normalized: orphenadrine citrate aspirin and caffeine |
Drug | Atland Pharmaceuticals, LLC | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| TOLMETIN SODIUM Normalized: tolmetin sodium |
Drug | Atland Pharmaceuticals, LLC | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 37 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 216 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 211 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 146 | 54 |
| Montelukast Sodium | Montelukast Sodium | 139 | 61 |
| Gabapentin | Gabapentin | 128 | 67 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 123 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 84 | 34 |
| Furosemide | Furosemide | 83 | 42 |
| Omeprazole | Omeprazole | 80 | 42 |
| Mounjaro | Tirzepatide | 75 | 19 |
| Losartan Potassium | Losartan Potassium | 74 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 25 |
| Lisinopril | Lisinopril | 58 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 19 |
| Trazodone Hcl | Trazodone Hcl | 55 | 18 |
| Metformin Hcl | Metformin Hcl | 54 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 18 |
| Allopurinol | Allopurinol | 47 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 20 |
| Jardiance | Empagliflozin | 43 | 14 |
| Baclofen | Baclofen | 42 | 24 |
| Farxiga | Dapagliflozin Propanediol | 42 | 14 |
| Azithromycin | Azithromycin | 40 | 32 |
| Eliquis | Apixaban | 37 | 13 |
| Celecoxib | Celecoxib | 36 | 14 |
| Carvedilol | Carvedilol | 35 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 18 |
| Nifedipine Er | Nifedipine | 33 | 12 |
| Famotidine | Famotidine | 31 | 15 |
| Clonidine Hcl | Clonidine Hcl | 30 | 15 |
| Ezetimibe | Ezetimibe | 30 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 17 |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | 14 |
| Ozempic | Semaglutide | 28 | suppressed |
| Levetiracetam | Levetiracetam | 27 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Simvastatin | Simvastatin | 24 | 15 |
| Indapamide | Indapamide | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | 15 |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Olanzapine | Olanzapine | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $312.11 · 27 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, BREZTRI, CAPLYTA, ELIQUIS, Kerendia, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, Ozempic, Rybelsus, TOLMETIN SODIUM, TRELEGY ELLIPTA, VOWST | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error